Literature DB >> 20730598

Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth.

Robert S Tolhurst1, Ross S Thomas, Fiona J Kyle, Hetal Patel, Manikandan Periyasamy, Andrew Photiou, Paul T R Thiruchelvam, Chun-Fui Lai, Marwa Al-Sabbagh, Rosemary A Fisher, Sayka Barry, Tatjana Crnogorac-Jurcevic, Lesley-Ann Martin, Mitch Dowsett, R Charles Coombes, Tahereh Kamalati, Simak Ali, Laki Buluwela.   

Abstract

Estrogen receptor-α (ERα) positive breast cancer frequently responds to inhibitors of ERα activity, such as tamoxifen, and/or to aromatase inhibitors that block estrogen biosynthesis. However, many patients become resistant to these agents through mechanisms that remain unclear. Previous studies have shown that expression of ERα in ERα-negative breast cancer cell lines frequently inhibits their growth. In order to determine the consequence of ERα over-expression in ERα-positive breast cancer cells, we over-expressed ERα in the MCF-7 breast cancer cell line using adenovirus gene transduction. ERα over-expression led to ligand-independent expression of the estrogen-regulated genes pS2 and PR and growth in the absence of estrogen. Interestingly, prolonged culturing of these cells in estrogen-free conditions led to the outgrowth of cells capable of growth in cultures from ERα transduced, but not in control cultures. From these cultures a line, MLET5, was established which remained ERα-positive, but grew in an estrogen-independent manner. Moreover, MLET5 cells were inhibited by anti-estrogens showing that ERα remains important for their growth. Gene expression microarray analysis comparing MCF-7 cells with MLET5 highlighted apoptosis as a major functional grouping that is altered in MLET5 cells, such that cell survival would be favoured. This conclusion was further substantiated by the demonstration that MLET5 show resistance to etoposide-induced apoptosis. As the gene expression microarray analysis also shows that the apoptosis gene set differentially expressed in MLET5 is enriched for estrogen-regulated genes, our findings suggest that transient over-expression of ERα could lead to increased cell survival and the development of estrogen-independent growth, thereby contributing to resistance to endocrine therapies in breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20730598     DOI: 10.1007/s10549-010-1122-6

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  11 in total

Review 1.  Intrinsic and Extrinsic Factors Governing the Transcriptional Regulation of ESR1.

Authors:  David K Lung; Rebecca M Reese; Elaine T Alarid
Journal:  Horm Cancer       Date:  2020-06-26       Impact factor: 3.869

2.  Modeling the estrogen receptor to growth factor receptor signaling switch in human breast cancer cells.

Authors:  Chun Chen; William T Baumann; Robert Clarke; John J Tyson
Journal:  FEBS Lett       Date:  2013-08-28       Impact factor: 4.124

Review 3.  The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance.

Authors:  Cynthie Wong; Shiuan Chen
Journal:  J Steroid Biochem Mol Biol       Date:  2012-01-08       Impact factor: 4.292

Review 4.  Drug resistance to targeted therapies: déjà vu all over again.

Authors:  Floris H Groenendijk; René Bernards
Journal:  Mol Oncol       Date:  2014-05-21       Impact factor: 6.603

5.  Support of a bi-faceted role of estrogen receptor β (ERβ) in ERα-positive breast cancer cells.

Authors:  Philip Jonsson; Anne Katchy; Cecilia Williams
Journal:  Endocr Relat Cancer       Date:  2014-01-30       Impact factor: 5.678

6.  Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer.

Authors:  Georgios Giamas; Aleksandra Filipović; Jimmy Jacob; Walter Messier; Hua Zhang; Dongyun Yang; Wu Zhang; Belul Assefa Shifa; Andrew Photiou; Cathy Tralau-Stewart; Leandro Castellano; Andrew R Green; R Charles Coombes; Ian O Ellis; Simak Ali; Heinz-Josef Lenz; Justin Stebbing
Journal:  Nat Med       Date:  2011-05-22       Impact factor: 53.440

7.  Down-regulation of estrogen receptor-alpha and rearranged during transfection tyrosine kinase is associated with withaferin a-induced apoptosis in MCF-7 breast cancer cells.

Authors:  Xuan Zhang; Ridhwi Mukerji; Abbas K Samadi; Mark S Cohen
Journal:  BMC Complement Altern Med       Date:  2011-10-06       Impact factor: 3.659

8.  The treatment of breast cancer using liposome technology.

Authors:  Sarah Brown; David R Khan
Journal:  J Drug Deliv       Date:  2012-02-21

9.  Liposomal Doxorubicin in the treatment of breast cancer patients: a review.

Authors:  Juan Lao; Julia Madani; Teresa Puértolas; María Alvarez; Alba Hernández; Roberto Pazo-Cid; Angel Artal; Antonio Antón Torres
Journal:  J Drug Deliv       Date:  2013-03-26

10.  Nuclear Receptor Signaling Atlas: Opening Access to the Biology of Nuclear Receptor Signaling Pathways.

Authors:  Lauren B Becnel; Yolanda F Darlington; Scott A Ochsner; Jeremy R Easton-Marks; Christopher M Watkins; Apollo McOwiti; Wasula H Kankanamge; Michael W Wise; Michael DeHart; Ronald N Margolis; Neil J McKenna
Journal:  PLoS One       Date:  2015-09-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.